@article {2210, title = {Analysis of Hepcidin and Interleukin-6 Levels among Transfusion-Dependent Thalassemia Patients With and Without Alloimmunization/Autoimmunization}, journal = {Pharmacognosy Journal}, volume = {16}, year = {2024}, month = {February 2024}, pages = {60-66}, type = {Original Article}, chapter = {60}, abstract = {

Background: Transfusion-dependent thalassemia (TDT) necessitates regular transfusions, resulting in complications such as iron overload, hemolytic anemia, and the emergence of alloantibodies/ autoantibodies. This situation poses challenges in obtaining compatible transfusions. Excessive iron and chronic hemolysis impact the elevation of Interleukin-6 (IL-6), initiating an inflammatory process that triggers hepcidin formation and influences antibody development. This study aims to analyze disparities in IL-6 and hepcidin levels and establish the correlation between IL-6 and hepcidin in TDT patients with and without alloimmunization/autoimmunization. Methods: Forty whole blood samples were collected from TDT patients with and without alloimmunization/autoimmunization, centrifuged, and the serum extracted, then stored in a refrigerator at -80{\textdegree}C. IL-6 and hepcidin levels were assessed using the ELISA method. The Mann-Whitney U test was employed to evaluate differences in hepcidin and IL-6 levels between the two groups. In contrast, the Spearman Correlation test was utilized to analyze the correlation between hepcidin and IL-6 levels. Results: IL-6 levels in the TDT group with alloimmunization/autoimmunization (3.64 pg/ mL) were significantly higher compared to the TDT group without alloimmunization/autoimmunization (1.41 pg/mL; p \< 0.05). Hepcidin levels in the TDT group with alloimmunization/autoimmunization (2,950.6 pg/mL) were significantly higher compared to the TDT group without alloimmunization/autoimmunization (1,599.6 pg/mL; p \< 0.05). The Spearman correlation test revealed a significant positive correlation between hepcidin and IL-6 levels in TDT patients with alloimmunization/autoimmunization (r = 0.764; p = 0.000). Additionally, a significant positive correlation was observed between hepcidin and IL-6 levels in TDT patients without alloimmunization/autoimmunization (r = 0.559; p = 0.010). Conclusion: IL-6 and hepcidin levels were elevated in TDT patients with alloimmunization/autoimmunization compared to those without. Interleukin-6 and hepcidin exhibited a positive correlation in both transfusion-dependent thalassemia groups.

}, keywords = {Anemia, Antibodies, Hepcidin, Interleukin-6, Transfusion-Dependent Thalassemia}, doi = {10.5530/pj.2024.16.9}, author = {Widya Firly Novitasari and Jusak Nugraha and Mia Ratwita Andarsini and Betty Agustina Tambunan} } @article {1977, title = {Analysis of Covid-19 Neutralizing Antibody Levels Post Vaccination using Ichroma{\texttrademark} and iFlash Covid-19 Nab}, journal = {Pharmacognosy Journal}, volume = {15}, year = {2023}, month = {March 2023}, pages = {171-174}, type = {Research Article}, chapter = {171}, abstract = {

Background: One of the efforts to control SARS-CoV-2 infection in health workers is vaccination. In this study, the levels of SARS-CoV-2 neutralizing antibody (nAb) in health workers were measured with Ichroma and iFlash. Methods: This study applied an observational analytic design with a prospective cohort and was conducted at Dr. Soetomo Regional Public Hospital, Surabaya, from January to November 2021. The population of this study included a total of 75 health workers after taking the second dose of the SARS-CoV-2 (Sinovac) vaccine. The Covid-19 NAb levels of the population were tested with Ichroma and iFlash on day 0 before vaccination, as well as days 14 and 28, and months 3 and 6 after vaccination. Results: The Friedman test indicated a significant difference in NAb levels according to the iFlash test on day 14, day 28, month 3, and month 6 compared to those before vaccination (p \< 0.05). The Wilcoxon test revealed a significant difference in NAb levels on day 14, day 28, month 3, and month 6. The results of the Cochran test showed a significant difference in the positivity of NAb according to the Ichroma test on day 14, day 28, month 3, and month 6 compared to those before vaccination (p \< 0.05). McNemar{\textquoteright}s test demonstrated that the COI at month 3 was not significantly different from that before vaccination; The COI at month 6 was not significantly different from those at days 14 and 28. The results of the Pearson correlation test and Bland{\textendash}Altman plot indicated a moderate correlation between Ichroma and iFlash (r = 0.592, p = 0.002). Conclusion: Neutralizing antibodies for Covid-19 were formed after day 14 and started to increase on day 28 and started to decrease in months 3 and 6. The levels of NAb for Covid-19 were measured with Ichroma and iFlash in roughly the same pattern and had a moderate positive correlation.

}, keywords = {Ichroma, iFlash., Neutralizing Antibody}, doi = {10.5530/pj.2023.15.25}, author = {Hartono Kahar and Sari Prabandari Prasetyaningrum and Munawaroh Fitriah and Aryati and Jusak Nugraha} } @article {2056, title = {Correlation of Apo E Gene Polymorphism with Recurrent Acute Coronary Syndrome}, journal = {Pharmacognosy Journal}, volume = {15}, year = {2023}, month = {June 2023}, pages = {450-453}, type = {Research Article}, chapter = {450}, abstract = {

Background: Recurrent cardiovascular disease (CVD) incidence puts patients at higher risk for mortality and morbidity. One of the CVD symptoms is acute coronary syndrome (ACS). Many genetic polymorphisms are CVD risk factors. This study{\textquoteright}s purpose was to investigate the correlation between recurrent ACS incidence and apolipoprotein E (ApoE) gene polymorphism. Method: Case-control design was used in this study. About 90 patients who visited the cardiology and internal medicine clinics at UNAIR Hospital in Surabaya, Indonesia, served as the study{\textquoteright}s subjects. There were 30 patients with recurrent ACS, 30 patients with a single ACS, and 30 patients with no history of cardiovascular disease. Afterward, using the polymerase chain reaction-restriction fragment length method, the ApoE gene polymorphism examination was carried out. The Tropical Disease Center UNAIR Laboratory conducted all laboratory testing. Results: In the recurrent ACS group, ApoE polymorphism genotype patterns were 5 subjects for ε2ε2 (16.67\%), 23 subjects for ε3ε3 (76.66\%), and 2 subjects for ε4ε4 (6.67\%). Meanwhile, in the single ACS group, ApoE polymorphism genotype patterns were 6 subjects for ε2ε2 (20\%), 22 subjects for ε3ε3 (73.4\%), 1 subject for ε4ε4 (3.33\%), and 1 subject for ε2ε3 (3.33\%). And, in the non- ACS group, ApoE polymorphism genotype patterns were4 subjects for ε2ε2 (13.34\%), 25 subjects for ε3ε3 (83.33\%), and1 subject for ε4ε4 (3.33\%). There was no correlation of ApoE gene polymorphism with recurrent ACS incidence by Chi-square analysis (p \> 0.05). Conclusion: ApoE gene polymorphism cannot significantly affect recurrent ACS incidence.

}, keywords = {Acute Coronary Syndrome, ApoE gene, PCR RFLP, Polymorphism, Public Health}, doi = {10.5530/pj.2023.15.100}, author = {Muhamad Robiul Fuadi and Jusak Nugraha and I Gde Rurus Suryawan and Hartono Kahar and Aryati and Gwenny Ichsan Prabowo and Budi Utomo and Reny I{\textquoteright}tishom} } @article {1779, title = {Mechanism of the Bioactive Sargassum cristaefolium in Inhibiting Inflammatory Mediators in a Nitroglycerin-Induced Migraine Model in Rats}, journal = {Pharmacognosy Journal}, volume = {14}, year = {2022}, month = {April 2022}, pages = {388-396}, type = {Research Article }, chapter = {388}, abstract = {

Background: Migraine headaches are a form of sterile neurogenic inflammation. The sterile inflammatory process of the trigeminal nerve releases the vasoactive neuropeptide CGRP which stimulates the release of inflammatory mediators. In the incidence of migraine there is an increase in TNF-α and IL-10. Sargassum cristaefolium ethanol extract contains flavonoids, alkaloids, triterpenoids, steroids, and tannins, which has analgesic and anti-inflammatory function. Method: Sargassum cristaefolium was extracted using maceration method with 70\% ethanol as solvent. Animal models were divided into 5 groups and given NTG induction 5 times with 1 day intervals, treated for 3 weeks. All data were analyzed using IBM SPSS version 26.0. Results: Sargassum cristaefolium ethanol extract - CGRP levels β: -0.26, p: 0.17; Sargassum cristaefolium ethanol extract - CGRP expression β: -0.04, p: 0.85; Sargassum cristaefolium ethanol extract - TNF-α levels β: -0.63, p: 0.01; Sargassum cristaefolium ethanol extract - TNF-α expression β: -0.40, p: 0.04; Sargassum cristaefolium ethanol extract - IL-10 levels β: 0.77, p: 0.00; Sargassum cristaefolium ethanol extract - IL-10 expression β: 0.45, p: 0.01. Conclusions: A significant path between the administration of Sargassum cristaefolium ethanol extract and a decrease in TNF-α and an increase in IL-10. But the effect of giving Sargassum cristaefolium ethanol extract on CGRP levels did not have a significant relationship.

}, keywords = {Inflammatory mediator, Migraine, Nitroglycerin, Sargassum cristaefolium}, doi = {10.5530/pj.2022.14.50}, author = {Olivia Mahardani Adam and Jusak Nugraha and Muhammad Hamdan and Agus Turchan} } @article {1712, title = {In silico Study on the Promising Active Components of Terpenoid and Fucoidon from Sargassum sp. in Inhibiting CGRP and TNF-α}, journal = {Pharmacognosy Journal}, volume = {13}, year = {2021}, month = {December 2021}, pages = {1715-1719}, type = {Research Article}, chapter = {1715}, abstract = {

Introduction: The new discovery of the active substance in Sargassum sp marks the new era for drug industry as it is very effective as the new migraine medication compared to analgesics which have already been popular previously in treating migraine. By using the in silico methods, this study intended to identify the preventive effect of the active substance in Sargassum sp within the stage of pain and inflammation development in migraine. In migraine pathophysiology, the clinical findings would build and verify the role of CGRP and TNF-α. Methods: This research applied a one-shot experimental study and by employing the potential test through PubChem (https://pubchem.ncbi.nlm.nih.gov/), the result of this study proved that tannins, terpenoids and fucoidone were contained in the active substance of Sargassum sp leading to the possession of potential as the drug to treat migraine. Results: Terpenoids and tannin binding affinity value is higher than other substances. Terpenoids and fucoidon had similar amino acid residues with controls. Seaweed metabolites have great potential as inhibitors of CGRP and TNF-α because the binding affinity score is close to control. Conclusion: The active substance in Sargassum sp has an inhibitory effect on the occurrence of CGRP and TNF-α in migraine based on in silico studies.

}, keywords = {CGRP, Fucoidone, in silico, Sargassum sp., Terpenoid, TNF-α.}, doi = {10.5530/pj.2021.13.221}, author = {Olivia Mahardani Adam and Jusak Nugraha and Mohammad Hasan Machfoed and Agus Turchan} }